Therapy for Crohn disease

Current Opinion in Gastroenterology

Volumn 16, Issue 4, 2000, Pages 318-323

  Sandborn, W J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INFLIXIMAB; INTERLEUKIN 11; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THALIDOMIDE;

ANUS FISTULA; ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENTEROCUTANEOUS FISTULA; HEALTH CARE COST; HUMAN; RECURRENT DISEASE; REMISSION;

EID: 0034463213     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200007000-00005     Document Type: Article

References (82)

1. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort
2. Inflammatory bowel disease: Medical cost algorithms
3. Inflammatory bowel disease: Costs of illness
4. Inflammatory bowel diseases: Health care and costs in Sweden in 1994
5. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial
6. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease
7. National Cooperative Crohn's Disease Study: Results of drug treatment
8. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
9. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease
10. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study
11. Prophylactic mesalamine decreases postoperative recurrence of Crohn's disease
12. Second trial of mesalamine therapy in the treatment of active Crohn's disease
13. A comparison of budesonide and mesalamine for active Crohn's disease
14. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adiusted for confounding variables
15. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI
16. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease
17. Low-dose budesonide treatment for prevention of postoperative recurrence for Crohn's disease: A multicentre randomized placebocontrolled trial
18. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled dose-ranging study
19. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease: A placebo controlled one year study
20. Low dose oral pH-modified release budesonide for maintenance of steroid induced remission in Crohn's disease
21. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease
22. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease
23. Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease
24. Clinical, biological and endoscopic Picture of attacks of Crohn's disease: Evolution on prednisolone
25. Endoscopic monitoring of Crohn's disease treatment: A prospective, randomized, clinical trial
26. Glucocorticoid treatment in ileal Crohn's disease: Relief of symptoms but not endoscopically viewed inflammation
27. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease
28. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine
29. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
30. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine
31. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease
32. 6-mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity
33. Lymphoma in Crohn's disease occurring in a patient on 6-MP
34. Traitement de la maladie de Crohn par l'azathioprine ou la 6-mercaptopurine: Etude retrospective chez 126 malades
35. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease
36. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
37. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine
38. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporine A and methotrexate in the treatment of inflammatory bowel diseases
39. Lymphoma in inflammatory bowel disease
40. Extracolonic malignancies in inflammatory bowel disease
41. Crohn's disease and cancer: A population-based cohort study
42. Fatal infectious mononucleosis: A severe complication in the treatment of Crohn's disease with azathioprine
43. Mixed pulmonary infection with Norcardia, Candida, methicillin-resistent Staphylococcus aureus, and group D Streptococcus species
44. Disseminated norcardiosis complicating medical therapy in Crohn's disease
45. Management of varicella infection during the course of inflammatory bowel disease
46. An unusual complication of immunosuppressive therapy in inflammatory bowel disease
47. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years experience
48. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease
49. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease
50. Methotrexate for the treatment of Crohn' disease
51. Methotrexate in chronic active Crohn's disease: A double-blind, randomized, Israeli multicenter trial
52. Methotrexate for chronic ulcerative colitis: A double-blind, randomized, Israeli multicenter trial
53. Methotrexate for the treatment of refractory Crohn's disease
54. Methotrexate in refractory Crohn's disease
55. Methotrexate in Crohn's disease: Results of a randomized, double-blind, placebo-controlled trial
56. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis
57. The absorption of methotrexate in patients with inflammatory bowel disease
58. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease
59. Plasma and rectal adenosine in inflammatory bowel disease: Effect of methotrexate
60. Tacrolimus (FK-506) treatment of fulminant colitis in a child
61. Preliminary report on the use of oral tacrolimus (FKS06) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease
62. Steroid-unresponsive acute attacks of inflammatory bowel disease: Immunomodulation by tacrolimus (FK506)
63. Combination therapy with oral tacrolimus (FKS06) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulas
64. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
65. Infliximab for the treatment of fistulas in patients with Crohn's disease
66. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha antibody for Crohn's disease
67. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
68. Endoscopic and histologic healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
69. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
70. Successful management of Crohn's disease of the ileoanal pouch with infliximab
71. Treatment of severe esophageal Crohn's disease with infliximab
72. The relationship between infliximab treatment and lymphoma in Crohn's disease
73. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
74. Treatment of chronic inflammatory bowel disease in glycogen storage disease type Ib with colony-stimulating factors
75. Cyclic neutropenia in Crohn's ileocolitis: Efficacy of granulocyte colony-stimulating factor
76. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor
77. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease
78. Thalidomide in Crohn's disease
79. Thalidomide in oral Crohn's disease refractory to conventional medical treatment
80. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
81. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
82. Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease